Press Release

Latest Data Confirms: ZEISS MyoCare Slows Progression of Myopia

Ongoing trials across Asia and Europe reconfirm effectiveness.

8 May 2025

Aalen, Germany | 8 May 2025 | ZEISS Vision Care

  • Two-year results from Asia show that both ZEISS MyoCare and ZEISS MyoCare S continue to significantly slow the progression of myopia.
  • One- year results from Europe show that ZEISS MyoCare slows myopia and reduces the risk of fast progression.
  • ZEISS MyoCare lenses are found to be equally effective across both Asian and European children.
  • In European studies, 84% of children adapted to ZEISS MyoCare lenses in less than three days.

The latest 1-year and 2-year results from the ongoing multi-center trials consistently demonstrate the slowing of progressive myopia in Asian and Caucasian children. Additionally, data confirms rapid adaptation to ZEISS MyoCare lenses. 

In two ongoing multi-center clinical trials across China and Europe, ZEISS MyoCare lenses are being assessed to ensure a comprehensive and robust evaluation of their effectiveness in slowing myopia. At the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) held at Salt Lake City, USA, ZEISS Vision Care showcased the latest findings.

ZEISS MyoCare lenses continue to slow myopia

In Asian children, after 2 years of wear, as compared to single vision lenses, ZEISS MyoCare is shown to have slowed myopia progression on average by 0.44D and 0.20mm and ZEISS MyoCare S by 0.41D and 0.17mm.1 In Caucasian children, after twelve months ZEISS MyoCare slowed myopia progression on average by 0.21D and 0.14mm and significantly reduced the risk of fast progression.2,3 Additionally, ZEISS MyoCare lenses were seen to significantly slow myopia irrespective of past progression.4
Although progression of myopia was higher in Asian eyes as compared to European eyes, ZEISS MyoCare lenses were effective in slowing myopia equally across both races.5

Asian children

ZEISS MyoCare

  • 0.44D

    average reduction of refractive error

  • 0.20mm

    average reduction of axial length progression

Caucasian children

ZEISS MyoCare

  • 0.21D

    average reduction of refractive error

  • 0.14mm

    average reduction of axial length progression

Fast adaptation to ZEISS MyoCare lenses in Europe

Children who adapt quickly to new lenses are more likely to wear them consistently, and good compliance has been determined to be a key factor for slowing myopia. Results indicated that 84% of ZEISS MyoCare lens wearers adapted to the lenses in less than three days. Additionally, when queried on subjective impressions a full 95%, 93% and 96% reported either “good or very good” distance vision, near vision, and vision when playing sports or with other daily activities, respectively.6

The posters presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) can be found here.

ZEISS, MyoCare and C.A.R.E. are trademarks of Carl Zeiss AG and/or other companies of the Carl Zeiss group.

ZEISS MyoCare and ZEISS MyoCare S are not available in the United States.

References and notes

(1) Chen X, et al. (2025, May 4-8). Slowing myopia progression with cylindrical annular refractive elements (CARE)- results from a 2-year prospective multi-central trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
(2) Alvarez-Peregrina, C., et al. (2025, May 4-8). Analysis of fast myopia progression and eye growth reversal in the Clinical Evaluation of MyoCare in Europe (CEME) study after 12 months wearing CARE lenses. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
(3) Alvarez-Peregrina, C., et al. Clinical Evaluation of MyoCare in Europe – the CEME Study Group. Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results. Ophthalmic Physiol Opt. 2025 Apr 29. doi: 10.1111/opo.13517. Epub ahead of print. PMID: 40296784.
(4) Ohlendorf, A., et al. (2025, May 4-8). Myopia progression in children: Comparison of progression one year before and during participation in a randomized controlled clinical trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
(5) Sankaridurg, P., et al. (2025, May 4-8). Myopia control efficacy in Asian versus European eyes with spectacle lenses incorporating cylindrical annular refractive elements (CARE). [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
(6) Sanchez-Tena, M.A., et al. (2025, May 4-8). Adaptation and Visual Performance of CARE Spectacle Lenses: Findings from the Clinical Evaluation of MyoCare in Europe (CEME) Study. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.

Press Contact Sarah Kopp

ZEISS Vision Care

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

 

ZEISS Vision Care
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.

Download

    • ZEISS Myopia Management

      Latest Data Confirms: ZEISS MyoCare Slows Progression of Myopia.

      1 MB


    • ZEISS MyoCare Slows Progression of Myopia

      Latest Data Confirms: ZEISS MyoCare Slows Progression of Myopia

      171 KB



Share this article